

# Ciara M Kelly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4499296/publications.pdf>

Version: 2024-02-01

25  
papers

3,489  
citations

623574

14  
h-index

642610

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

8477  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. <i>Journal of Clinical Oncology</i> , 2022, 40, 997-1008.	0.8	13
2	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1507-1517.	3.2	3
3	Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. , 2022, 10, e004149.		20
4	Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 939-947.	3.2	10
5	Interpreting Nonrandomized Clinical Trial Data in Low-Grade Sarcoma: Differentiating Clinical Benefit From Indolent Disease Is Key. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
6	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. <i>Nature Communications</i> , 2022, 13, .	5.8	63
7	Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	21
8	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	51
9	The emerging role of immunotherapy for the treatment of sarcoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 730-738.	0.8	16
10	The management of metastatic GIST: current standard and investigational therapeutics. <i>Journal of Hematology and Oncology</i> , 2021, 14, 2.	6.9	107
11	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. <i>Cancer Medicine</i> , 2021, 10, 4221-4227.	1.3	8
12	Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. <i>Frontiers in Oncology</i> , 2021, 11, 725484.	1.3	4
13	Genomic Profiling Identifies Association of <i>IDH1/IDH2</i> Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 419-427.	3.2	60
14	HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. <i>Clinical Cancer Research</i> , 2020, 26, 5448-5455.	3.2	12
15	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. <i>JCO Precision Oncology</i> , 2020, 4, 1350-1360.	1.5	18
16	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
17	A phase Ib study of BCGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	1.2	32
18	HER2: An emerging target in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 560-571.	1.0	67

#	ARTICLE	IF	CITATIONS
19	From Shelf to Bedside—Wearable Electronic Activity Monitoring Technologies Might Assist Oncologists in Functional Performance Status Assessment of Older Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2017, 16, e115-e118.	1.0	9
20	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
21	Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma—A New Look at an Old Drug. <i>Oncologist</i> , 2017, 22, 1102-1106.	1.9	39
22	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
23	The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 750-762.	0.6	45
24	Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. <i>Journal of Oncology</i> , 2016, 2016, 1-13.	0.6	145
25	Targeted Therapy in Older Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2635-2646.	0.8	36